This database contains 523 studies, archived under the term: "Alzheimer’s Disease"
Click here to filter this large number of results.
Persons with Alzheimer’s disease make phone calls independently using a computer-aided telephone system
Perilli, Viviana,
Lancioni, Giulio E.,
Singh, Nirbhay N.,
O’Reilly, Mark F.,
Sigafoos, Jeff,
Cassano, Germana,
Cordiano, Noemi,
Pinto, Katia,
Minervini, Mauro G.,
Oliva, Doretta
This study assessed whether four patients with a diagnosis of Alzheimer’s disease could make independent phone calls via a computer-aided telephone system. The study was carried out according to a non-concurrent multiple baseline design across participants. All participants started with baseline during which the telephone system was not available, and continued with intervention in which […]
The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study
Padala, Kalpana P.,
Padala, Prasad R.,
McNeilly, Dennis P.,
Geske, Jenenne A.,
Sullivan, Dennis H.,
Potter, Jane F.
Background: Statins are well-known for their cardiovascular benefits. However, the cognitive effects of statins are not well understood. We hypothesized that individuals with preexisting dementia would be more vulnerable to statin-related cognitive effects.; Objective: The aim of this study was to evaluate the impact on cognition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin) discontinuation and rechallenge […]
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, Susanne,
Deptula, Dennis,
Thurfjell, Lennart,
Barkhof, Frederik,
Bohrmann, Bernd,
Brooks, David J.,
Klunk, William E.,
Ashford, Elizabeth,
Yoo, Kisook,
Xu, Zhi-Xin,
Loetscher, Hansruedi,
Santarelli, Luca
Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]
Alzheimer’s disease: is pacemaker implantation safe?
Osmonov, Damirbek,
Ozcan, Kazim Serhan,
Altay, Servet,
Erdinler, Izzet,
Yildirim, Ersin,
Türkkan, Ceyhan,
Canga, Yigit,
Alper, Ahmet Taha,
Cakmak, Nazmiye,
Gürkan, Kadir
Aim: To evaluate the safety of pacemaker implantation in patients with Alzheimer’s disease (AD).; Methods: We reviewed all cases admitted to our institution between January 2008 and June 2009, with symptomatic bradyarrhythmia for whom a permanent pacemaker was implanted. Beginning in June 2009, we prospectively collected data from all patients with the same diagnosis and […]
Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease
Munro, Cynthia A.,
Longmire, Crystal Flynn,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine E.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objectives: Although many depressed patients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo.; Design: Placebo-controlled, randomized, double-blind trial.; Setting: Outpatient memory […]
Physical and cognitive stimulation in Alzheimer Disease. the GAIA Project: a pilot study
Maci, Tiziana,
Pira, Francesco Le,
Quattrocchi, Graziella,
Nuovo, Santo Di,
Perciavalle, Vincenzo,
Zappia, Mario
Several data suggest that physical activity and cognitive stimulation have a positive effect on the quality of life (QoL) of people with Alzheimer’s disease (AD), slowing the decline due to the disease. A pilot project was undertaken to assess the effect of cognitive stimulation, physical activity, and socialization on patients with AD and their informal […]
Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer’s disease: friend or foe?
Kovacs, Janos,
Pákáski, Magdolna,
Juhasz, Anna,
Feher, Agnes,
Drótos, Gergely,
Fazekas, Csilla Orsike,
Horvath, Tamas Laszlo,
Janka, Zoltan,
Kálmán, János
Throughout the natural progression of Alzheimer’s disease (AD), the body mass index (BMI) decreases. This is believed to be brought on by the disturbance in the central lipid metabolism, but the exact mechanism is yet unknown. Adipokines (adiponectin, leptin), hormones produced by the adipose tissue, change glucose and lipid metabolism, and have an anorectic effect […]
Evaluation of the regional cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer’s disease using 3DSRT
Kimura, Noriyuki,
Kumamoto, Toshihide,
Masuda, Teruaki,
Hanaoka, Takuya,
Okazaki, Toshio,
Arakawa, Ryuki
Background: We attempt to evaluate objectively the regional cerebral blood flow (rCBF) changes during long-term donepezil therapy and the relationship between the clinical response and rCBF change in patients with Alzheimer’s disease (AD).; Patients and Methods: Thirty-one patients with mild-to-moderate AD (11 men, 20 female; mean age, 76.2 ± 6.7 years) were treated with donepezil […]
Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study
Kasuya, Masashi,
Meguro, Kenichi,
Okamura, Nobuyuki,
Funaki, Yoshihito,
Ishikawa, Hiroyasu,
Tanaka, Naofumi,
Iwata, Ren,
Yanai, Kazuhiko
The aim of the study was to predict donepezil responders among patients with Alzheimer disease (AD) based on cognitive tests and positron emission tomography. The Mini-Mental State Examination, Digit Symbol subtest (DigSm) of Wechsler Adult Intelligence Scale Revised, and Trail-Making Test A were administered for 80 patients with AD to assess global function, attention, and […]